Valuation : Aquestive Therapeutics, Inc.

Market Cap 655M 565M 532M 484M 911M 62.18B 916M 6.28B 2.45B 31.63B 2.46B 2.41B 105B P/E 2026 *
-10.2x
P/E 2027 * -10.9x
Enterprise Value 577M 498M 468M 427M 802M 54.78B 807M 5.54B 2.15B 27.86B 2.17B 2.12B 92.39B EV / Sales 2026 *
11.6x
EV / Sales 2027 * 9.67x
Free-Float
97.16%
Yield 2026 *
-
Yield 2027 * -
1 day+2.54%
1 week+3.15%
Current month+2.54%
1 month+41.81%
3 months+31.00%
6 months+31.00%
Current year-18.89%
1 week 4.91
Extreme 4.91
5.4
1 month 3.65
Extreme 3.65
5.41
Current year 2.93
Extreme 2.93
6.59
1 year 2.93
Extreme 2.93
7.55
3 years 1.25
Extreme 1.2514
7.55
5 years 0.62
Extreme 0.618
7.55
10 years 0.62
Extreme 0.618
20.7
Manager TitleAgeSince
Chief Executive Officer 50 2022-05-16
Director of Finance/CFO 67 2020-12-30
Compliance Officer - 2026-04-01
Director TitleAgeSince
Chairman 72 2024-03-31
Director/Board Member 60 2003-12-31
Director/Board Member 50 2022-05-16
Date Insider Type Main position Quantity % Market Cap. Importance
8/17/26 Sell

Chief Executive Officer

-25,000 0.0199%
8/14/26 Tax

Executive/Senior Manager

-2,714 0.0022%
7/16/26 Sell

Chief Executive Officer

-20,369 0.0162%
Change 5-day change 1-year change 3-year change Capi.($)
+2.54%+3.15%+38.99%+213.77% 641M
+0.28%-5.97%+58.34%+108.22% 1,031B
+2.01%-0.71%+53.07%+68.99% 641B
+1.39%-2.18%+23.57%+75.43% 453B
-1.50%-7.04%+33.55%+33.94% 349B
+6.25%+2.04%+28.97%+46.57% 290B
-0.07%-4.12%+0.95%+11.79% 252B
+1.92%-0.93%+52.28%+70.67% 232B
+0.51%-4.52%-19.50%-54.83% 201B
+2.45%+0.77%+32.71%+95.59% 181B
Average +1.71%-2.30%+30.29%+67.01% 363.04B
Weighted average by Cap. +1.60%-3.40%+38.39%+66.42%

Financials

2026 *2027 *
Net sales 49.93M 43.07M 40.51M 36.91M 69.4M 4.74B 69.78M 479M 186M 2.41B 187M 183M 7.99B 67.77M 58.46M 54.99M 50.1M 94.2M 6.43B 94.71M 650M 253M 3.27B 254M 249M 10.85B
Net income -63.62M -54.88M -51.62M -47.03M -88.43M -6.04B -88.91M -610M -238M -3.07B -239M -234M -10.18B -60.23M -51.95M -48.87M -44.52M -83.72M -5.72B -84.17M -578M -225M -2.91B -226M -221M -9.64B
Net Debt -78M -67.28M -63.29M -57.66M -108M -7.4B -109M -748M -291M -3.77B -293M -287M -12.49B -
Logo Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. It has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The Company is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.
Employees
147
Date Price Change Volume
26-09-01 US$5.240 +2.54% 2,163,655
26-08-31 US$5.110 +1.79% 1,908,012
26-08-28 US$5.020 -2.71% 2,517,467
26-08-27 US$5.160 -4.27% 3,663,314
26-08-26 US$5.390 +6.10% 3,412,030
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
5.220USD
Average target price
9.333USD
Spread / Average Target
+78.80%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AQST Stock